Signum Surgical, the medical technology company developing solutions to treat colorectal diseases, has been granted a new patent by the US Patent Office covering its BioHealx device. Signum’s intellectual property portfolio now consists of 35 patents globally, including five issued US patents owned or under license.
Johnny Bambury Johnny Bambury Photography
Signum Surgical - BioHealx
24/01/2019 SIGNUM SURGICAL - BioHealx Photo: Johnny Bambury
Moshe Zilversmit, co-founder and CEO of Signum Surgical, said: “We are pleased to receive another US patent covering our innovative BioHealx technology which is focused on the treatment of anal fistula. Our growing IP portfolio is a key asset for future development and bringing this technology to market. BioHealx has the potential to transform the lives of patients suffering from this debilitating condition.”
Headquartered in Galway, Signum Surgical is focused on developing minimally invasive technologies to treat colorectal diseases, firstly introducing the BioHealx technology to address the treatment of anal fistula. This painful colorectal condition affects one in 5,000 people worldwide and in the United States over 90,000 surgeries are performed annually to treat anal fistula. Current treatment options are often unsuccessful, which frequently result in inadequate or slow healing, a high risk of incontinence, and repeat procedures.
Developed in collaboration with expert colorectal surgeons, BioHealx will enable surgeons to treat anal fistula with a minimally invasive outpatient procedure, featuring a single use, bioabsorbable implant that is designed to close the fistula tract and dissolve in the body after treatment. The single-operation approach is designed to promote healing, prevent reinfection, and protect patient continence. The BioHealx technology has the potential to eliminate the need for multiple surgeries and substantially reduce surgical trauma and healing time, while reducing costs for patients and the overall healthcare system.
